Glucagon-Like Peptide-1 (GLP-1) Use Linked to Pediatric Deficiencies

First-Year Nutritional Deficiencies in Pediatric Patients

Nearly one in six children prescribed glucagon-like peptide-1 (GLP-1) receptor agonists received a diagnosis for a nutritional deficiency within their first year of treatment. Researchers from Ann & Robert H. Lurie Children's Hospital of Chicago published the findings in the journal Childhood Obesity. The observational study tracked 2,031 patients aged 10 to 17 between 2017 and 2022.

Overall, 16.8% of participants developed a diagnosed deficiency during that initial 12-month period. None had a documented deficiency before starting medication. Clinicians prescribed the drugs for weight loss, prediabetes, or type 2 diabetes.

• The study examined 2,031 patients aged 10 to 17 who met continuous insurance enrollment criteria.
• A total of 16.8% received a nutritional deficiency diagnosis within 12 months of starting treatment.
• Prescribed medications included liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%).

Vitamin D Rates and Skeletal Development Concerns

Vitamin D deficiency was the most frequent diagnosis, occurring in 12.4% of pediatric patients within one year of treatment initiation. Bone mass accumulates rapidly during adolescence. Senior author Justin Ryder stated that adolescent development requires adequate levels of vitamin D, iron, and calcium.

Insufficient levels of those specific nutrients create lasting risks for skeletal structure. Growth spurts demand steady nutrient intake. Reduced appetite from the medication can lead young patients to consume fewer total micronutrients.

• Vitamin D deficiency occurred in 12.4% of children within the first year on medication.
• Researchers highlighted vitamin D, iron, and calcium as three nutrients needing focused attention.
• Adolescent pubertal stages represent a sensitive window for bone accumulation and physical development.

Gaps in Early Clinical Nutrition Counseling

Only 5% of pediatric patients received professional nutritional counseling within 30 days of starting a GLP-1 medication. Referral numbers improved slightly over extended follow-up. Even after six months of active prescription use, fewer than 25% had seen a nutrition professional.

The study authors advised that dietary support must start immediately when prescribing these therapies. Proactive monitoring helps identify intake drops early. Waiting for a formal deficiency diagnosis exposes developing bodies to avoidable physical strain.

• Only 5% of young patients attended nutritional counseling within their first 30 days of therapy.
• Less than 25% of patients had received nutritional counseling by six months.
• Study authors recommend pairing dietary management with initial drug therapy rather than waiting for lab deficiencies.

Study Design and Observational Claims Data Limits

The analysis relied on national administrative insurance claims covering more than 100 million individuals from 2017 through 2022. Claims data record billing codes rather than precise dietary recall or daily blood lab values. Diagnoses might reflect only patients whose doctors ordered specific laboratory screenings.

In addition, 78.6% of the cohort took liraglutide, while semaglutide represented 9.1% and dulaglutide made up 10.4%. Prescription distributions in pediatric care continue to change over time. Families managing pediatric metabolic care should discuss scheduled lab monitoring with their prescribing physician.

• The dataset relied on insurance billing codes from 2017 to 2022 across 100 million total covered individuals.
• Liraglutide accounted for 78.6% of prescriptions in the cohort, with newer agents representing smaller shares.
• Billing records may underestimate true deficiencies if clinicians do not order routine blood testing.